Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

181. Ablative techniques for the treatment of localised prostate cancer

cryotherapy, irreversible electroporation, MRI-guided laser ablation and radiofrequency ablation, may address this clinical need, as there is some evidence that they have less toxicity than conventional therapies. However, the efficacy of these therapies is unclear, as several studies have shown high rates of persistent malignancy in the prostate glands so treated. Given that ablative techniques are offered as curative therapies for early prostate cancer and they are competing with well-established (...) with Prostate Cancer'. J Urol. 4. Ting, F., Tran, M. et al (2016). 'Focal irreversible electroporation for prostate cancer: Functional outcomes and short-term oncological control'. Prostate Cancer and Prostatic Diseases, 19 (1), 46-52. 5. Valerio, M., Stricker, P. D. et al (2014). 'Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer'. Prostate Cancer and Prostatic Diseases, 17 (4), 343-7. 6. Eggener, S. E., Yousuf, A. et al (2016

2018 COAG Health Council - Horizon Scanning Technology Briefs

182. Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy

recurrence of prostate cancer; however, questions remain about the long-term efficacy for local and distant tumor control and survival. Relevant Questions: Does salvage cryoablation provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with recurrent prostate cancer following failure of RT? Does salvage cryoablation provide acceptable outcomes with regard to urinary function, prostate symptoms, and sexual function? How does salvage (...) cryoablation compare with other salvage treatment options for recurrent prostate cancer, including radical prostatectomy (RP)? Is salvage cryoablation safe, and what are the related complications? Have definitive patient selection criteria been established for salvage cryoablation treatment for recurrent prostate cancer? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Chronic Disease; Cryosurgery; Humans; Male; Neoplasm Recurrence, Local

2018 Health Technology Assessment (HTA) Database.

183. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer

control to improve survival. Controversy: Locally ablative therapies such as cryoablation may have less morbidity compared with other primary treatment options for localized prostate cancer; however, questions remain about the long-term efficacy for local and distant tumor control and survival. Relevant Questions: Does cryoablation provide effective local tumor control and acceptable rates of remission and long-term disease-free survival in patients with primary localized prostate cancer? Does (...) inserted cryoprobes to freeze and, thereby, destroy cancerous prostate tissue. This outpatient procedure has been evaluated for patients with prostate cancer who prefer a less invasive option than prostatectomy or who are not appropriate surgical candidates. Rationale: The goals of the minimally invasive cryoablation treatment for localized prostate cancer are to use focused cryoablation energy to ablate the entire prostate gland or the cancer-containing part of the gland and achieve complete tumor

2018 Health Technology Assessment (HTA) Database.

184. Localised prostate cancer - immediate treatment, or not?

Localised prostate cancer - immediate treatment, or not? Prescrire IN ENGLISH - Spotlight ''Localised prostate cancer - immediate treatment, or not?'', 1 February 2018 {1} {1} {1} | | > > > Localised prostate cancer - immediate treatment, or not? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the February issue of Prescrire International (...) : Localised prostate cancer - immediate treatment, or not? FREE DOWNLOAD In patients with localised prostate cancer, the principal therapeutic options are: monitoring without initial treatment, prostatectomy and radiotherapy. Results of a comparative randomised trial have provided some useful data for providing information to patients. Full text available for free download. Summary In a randomised trial including 1643 patients with localised prostate cancer, all detected by PSA screening, the mortality

2018 Prescrire

185. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database Full Text available with Trip Pro

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database The aim of this study is to describe the trends and factors that influence the initial treatment of men with localized prostate cancer (PC) in the United States between 2004 and 2014.The National Cancer Institute's Surveillance, Epidemiology and End Results database was used to identify patients with primary prostate adenocarcinoma between 2004 and 2014. Patients were staged (...) in accordance with the American Joint Committee on Cancer 7th edition criteria and stratified according to the National Comprehensive Cancer Network guidelines risk group classification. Descriptive statistics describing treatment patterns by year of diagnosis, age, risk group, insurance status, and region were performed.A total of 460,311 male patients were identified with sufficient information to be categorized into National Comprehensive Cancer Network risk groups. Overall, 30.9% of patients had low

2018 Advances in radiation oncology

186. Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030 Full Text available with Trip Pro

Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030 Prostate cancer is the second most common malignancy among men worldwide, and it poses a significant public health burden that has traditionally been limited mostly to developed countries. However, the burden of the disease is expected to increase, affecting developing countries, including Thailand. We undertook an analysis to investigate current and future trends (...) of prostate cancer in the province of Songkhla, Thailand, using data from the Songkhla Cancer Registry from 1990 to 2013.Joinpoint regression analysis was used to examine trends in age-adjusted incidence and mortality rates of prostate cancer and provide estimated annual percent change (EAPC) with 95% CIs. Age-period-cohort (APC) models were used to assess the effect of age, calendar year, and birth cohort on incidence and mortality rates. Three different methods (Joinpoint, Nordpred, and APC) were used

2018 Journal of global oncology

187. Targeting protein myristoylation for the treatment of prostate cancer Full Text available with Trip Pro

Targeting protein myristoylation for the treatment of prostate cancer 29556510 2018 11 14 2331-4737 5 1-2 2018 Jan Oncoscience Oncoscience Targeting protein myristoylation for the treatment of prostate cancer. 3-5 10.18632/oncoscience.391 Sulejmani Essilvo E Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens,Athens, GA 30602, USA. Cai Houjian H Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia (...) , Athens,Athens, GA 30602, USA. eng R01 CA172495 CA NCI NIH HHS United States Editorial 2018 01 22 United States Oncoscience 101636666 2331-4737 B13 N-myristoyltransferase Src kinase myristoyl-CoA prostate cancer CONFLICTS OF INTEREST E. Sulejmani and H. Cai have no conflicts of interest to report. 2018 01 15 2018 01 15 2018 3 21 6 0 2018 3 21 6 0 2018 3 21 6 1 epublish 29556510 10.18632/oncoscience.391 391 PMC5854285 Nat Commun. 2014 Sep 26;5:4919 25255805 J Biol Chem. 2017 Nov 10;292(45):18422-18433

2018 Oncoscience

188. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. Full Text available with Trip Pro

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age (...) at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction

2018 BMJ

189. Erleada for Castrate Resistant Prostate Cancer - Details

Erleada for Castrate Resistant Prostate Cancer - Details Erleada for Castrate Resistant Prostate Cancer - Details | CADTH.ca Find the information you need Erleada for Castrate Resistant Prostate Cancer - Details Erleada for Castrate Resistant Prostate Cancer - Details Project Number pCODR 10133 Brand Name Erleada Generic Name Apalutamide Strength 60 mg Tumour Type Genitourinary Indication Castrate Resistant Prostate Cancer Funding Request non-metastatic castrate resistant prostate cancer (nm

2018 CADTH - Pan Canadian Oncology Drug Review

190. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. Full Text available with Trip Pro

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. Most prostate cancer patients develop castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment. CRPC growth is mediated mostly by androgen receptor signalling driven by primary androgens synthesised largely by the CYP17A1 enzyme.To evaluate the safety profile and dose-limiting toxicities of ODM-204 (...) looked at the safety of ODM-204, a novel dual inhibitor of CYP17A1 and the androgen receptor, in castration-resistant prostate cancer patients. ODM-204 treatment was found to be well tolerated, and it also reduced both serum testosterone and prostate-specific antigen levels, but the properties of the molecule prevent further development.Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2018 European urology focus Controlled trial quality: uncertain

191. Prostate cancer screening with prostate-specific antigen (PSA) test Full Text available with Trip Pro

imaging (MRI), bone scan, and computed tomography, are often also performed, especially in men presenting with higher risk disease, to check for disease spread. Screening controversy For many reasons, PSA screening remains controversial. Advocates often base their opinions on the European Randomised study of Screening for Prostate Cancer (ERSPC), which suggests that screening may reduce the long term risk of prostate cancer-specific mortality by at least 9% (relative reduction). They also note (...) that substantial observational evidence indicates a reduction in advanced disease and reduction in prostate cancer mortality, which they attribute to the introduction of PSA screening. Opponents of PSA screening highlight the indolent natural course of prostate cancer, citing systematic reviews that reported little or no impact of PSA screening on overall and prostate cancer-specific mortality. Opponents also suggest that the harms and burden from overdiagnosis and overtreatment resulting in unnecessary

2018 BMJ Rapid Recommendations

192. Management of locally advanced and metastatic prostate cancer

cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 May 26]. Available from: . Management of locally advanced and metastatic prostate cancer Contents Download Clinical questions: Androgen deprivation therapy (ADT) Radiotherapy Radiotherapy and androgen deprivation therapy (ADT) Surgery Surgery plus androgen deprivation therapy Pathologic T3/T4 disease post radical surgery (Patients with extra capsular extension, seminal vesicle involvement or positive surgical margins) Node-positive (...) Management of locally advanced and metastatic prostate cancer Management of locally advanced and metastatic prostate cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions Cite this guideline Cancer Council Australia Advanced Prostate Cancer Guidelines Working Party. Management of locally advanced and metastatic prostate

2018 Cancer Council Australia

193. High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer

the disease, while preserving continence and, if possible, potency [1] (B0001). Radiation therapy (RT) is another definitive treatment strategy in which a therapeutic dose of radi- ation is delivered to the tumour (either as external beam, brachytherapy, or a combination of both) while minimising the radiation to normal tissue. External beam RT (EBRT) utilises an external source of radiation to treat the prostate gland and a margin of adjacent normal tissue. Brachy- therapy directly implants a radioactive (...) source within the prostate, thus providing the highest dose of radiation. Its aim is to maximise irradiation of the tumour while minimising radiation to normal tissue [11] (B0001). Health problem PCa is the most common non-skin cancer in men in Europe [1]. Localised PCa is often indolent, and has no impact on health, even without treatment [12-14] (A0002). The incidence of PCa is higher in Northern and Western Europe compared with other areas of Europe, whereas incidence rates in Eastern and Southern

2018 EUnetHTA

194. Enzalutamide (Xtandi) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.

Enzalutamide (Xtandi) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84. Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC) - Repository of AIHTA GmbH English | Browse - - - Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC) Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (...) (CRPC). DSD: Horizon Scanning in Oncology 84. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 767kB Abstract Castration-resistant prostate cancer (CRPC) is a prostate cancer that keeps growing even when the testosterone level is reduced to very low levels. Enzalutamide (Xtandi®) is an orally bioavailable, organic, non-steroidal small-molecule androgen receptor (AR) signalling inhibitor. The US Food and Drug Administration (FDA) approved enzalutamide

2018 Austrian Institute of Health Technology Assessment

195. High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support Document 37/ Update 2018.

High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support Document 37/ Update 2018. High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018 - Repository of AIHTA GmbH English | Browse - - - High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018 Erdos, J. and Fischer, S. (2018): High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support (...) Document 37/ Update 2018. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 1MB Abstract Prostate cancer is one of the most common cancer types in men in Europe. We reviewed current evidence on efficacy and safety of high-intensity focused ultrasound (HIFU) as primary or salvage therapy compared to radiotherapy, active surveillance, watchful waiting, and radical prostatectomy in the treatment of low and intermediate-risk localised or locally recurrent prostate cancer

2018 Austrian Institute of Health Technology Assessment

196. Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107.

effects. The conclusion is accordingly that there is at present inadequate and insufficient evidence to show that IRE, SBRT and PT have either a positive impact on survival and quality of life or the ability to prevent or delay prostatectomy. Item Type: Project Report Keywords: Cancer, prostate, tumour, radiation therapy Subjects: > > > > > Language: German Series Name: HTA-Projektbericht 107 Deposited on: 02 Jul 2018 10:14 Last Modified: 15 Jul 2020 17:57 Repository Staff Only: © Copyright , (...) Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107. Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer - Repository of AIHTA GmbH English | Browse - - - Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer Schmidt, L. and Lohr, P. and Wild, C. (2018): Stereotactic

2018 Austrian Institute of Health Technology Assessment

197. Prostate cancer: Medroxyprogesterone acetate

Prostate cancer: Medroxyprogesterone acetate Medroxyprogesterone acetate | Prescribing information | Prostate cancer | CKS | NICE Search CKS… Menu Medroxyprogesterone acetate Prostate cancer: Medroxyprogesterone acetate Last revised in October 2017 Medroxyprogesterone acetate Indications Management of hot flushes caused by long-term androgen suppression in men with prostate cancer. This indication is outwith the product licence. [ ; ] Dose For the treatment of hot flushes caused by long-term (...) androgen suppression in men. 20 mg daily, initially for a period of 10 weeks. Treatment should be evaluated at the end of this period. [ ] Contraindications and cautions Do not prescribe medroxyprogesterone acetate to: Acute liver disease, or a history of liver disease. Previous idiopathic, or current venous thromboembolism. Active or recent arterial thromboembolic disease (for example, angina, myocardial infarction). Porphyria. Prescribe medroxyprogesterone acetate with caution to men with: Asthma

2018 NICE Clinical Knowledge Summaries

198. Prostate cancer: Cyproterone acetate

diseases (including Dubin–Johnson syndrome or Rotor syndrome). Meningioma or a history of meningioma. Previous or existing liver tumours (only if these are not due to metastases from carcinoma of the prostate). Wasting diseases (with the exception of inoperable carcinoma of the prostate). Existing thrombosis or embolism. Prescribe cyproterone acetate with caution to men with: Diabetes mellitus. Sickle cell anaemia. A history of arterial or venous thrombotic or thromboembolic events (for example deep (...) Prostate cancer: Cyproterone acetate Cyproterone acetate | Prescribing information | Prostate cancer | CKS | NICE Search CKS… Menu Cyproterone acetate Prostate cancer: Cyproterone acetate Last revised in October 2017 Cyproterone acetate Indications Cyproterone acetate is licensed for the treatment of hot flushes in men with prostate cancer who are receiving treatment with gonadorelin analogues or who have had orchidectomy. It is also licensed: To suppress tumour flare with initial gonadorelin

2018 NICE Clinical Knowledge Summaries

199. Prostate cancer

Prostate cancer Prostate cancer | Topics A to Z | CKS | NICE Search CKS… Menu Prostate cancer Prostate cancer Last revised in October 2017 Prostate cancer is a malignant tumour of the prostate. Almost all cancers of the prostate (95%) are adenocarcinomas. Diagnosis Management Prescribing information Background information Prostate cancer: Summary Prostate cancer is a malignant tumour of the prostate. Almost all cancers of the prostate (95%) are adenocarcinomas. Prostate cancer is multifocal (...) — the different foci may be caused by different genetic mutations, which can differ greatly in growth rate and ability to metastasize. Most prostate cancers are indolent and grow slowly — a minority are aggressive and invade local structures or metastasize to remote tissues. Localized prostate cancer usually develops in the outer zone of the prostate, where it seldom causes symptoms. Locally advanced prostate cancer extends beyond the capsule of the prostate and is often asymptomatic when diagnosed

2018 NICE Clinical Knowledge Summaries

200. Prostate cancer: Scenario: Management

and Care Excellence (NICE) guideline Prostate cancer: diagnosis and management [ ]. Radical treatments What is radical prostatectomy, and when is it appropriate treatment for prostate cancer? The aim of radical prostatectomy is to remove the entire prostate gland and eradicate the disease. It can be performed by open, laparoscopic, or robot-assisted surgery. Risks associated with radical prostatectomy include urinary incontinence, erectile dysfunction, and incomplete resection of the tumour. Complete (...) tumour removal is not always achieved, and approximately 20% of men develop biochemical or clinical recurrence of prostate cancer. Radical prostatectomy is an appropriate treatment option for: Localized prostate cancer — it can be considered in men at low prognostic risk, and is a preferred option for men at intermediate risk and those at high risk who have a realistic chance of gaining long-term control of the disease. It is not common to offer it to men older than 70 years of age. Biochemical

2018 NICE Clinical Knowledge Summaries